S-Propargylcysteine

S-Propargylcysteine (SPRC), a structural analog of S-allyl cysteine (SAC), is a slow H2S-releasing compound. S-Propargylcysteine reduces Ca2+ accumulation and inflammatory cytokines, inhibits STAT3, and elevates p53 and Bax. S-Propargylcysteine has anti-inflammatory activity and protects mice against acute pancreatitis. S-Propargylcysteine also has cardioprotective, neuroprotective acitivties[1][2].

Product Specifications

CAS Number

[3262-64-4]

Product Name Alternative

SPRC

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

MDM-2/p53; STAT

Type

Reference compound

Related Pathways

Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/s-propargylcysteine.html

Purity

97.0

Solubility

H2O : 25 mg/mL (ultrasonic)

Smiles

O=C([C@H](CSCC#C)N)O

Molecular Formula

C6H9NO2S

Molecular Weight

159.21

Precautions

H302, H315, H319, H335

References & Citations

[1]Sidhapuriwala JN, et al. Effects of S-propargyl-cysteine (SPRC) in caerulein-induced acute pancreatitis in mice. PLoS One. 2012;7 (3) :e32574.|[2]Wen YD, et al. The Pharmacological Effects of S-Propargyl-Cysteine, a Novel Endogenous H2S-Producing Compound. Handb Exp Pharmacol. 2015;230:325-36.